53462-88-7

Usage

Uses

Used in Pharmaceutical Industry:
3-formyl-1H-Indole-4-carboxylic acid methyl ester is utilized as a key intermediate in the synthesis of various drugs and pharmaceutical compounds. Its unique structure allows it to be a valuable building block for the development of new medications, contributing to the advancement of healthcare solutions.
Used in Organic Synthesis:
In the realm of organic synthesis, 3-formyl-1H-Indole-4-carboxylic acid methyl ester serves as a versatile reagent for the creation of a wide array of organic molecules. Its ability to participate in various chemical reactions makes it instrumental in the production of complex organic compounds.
Used in Medicinal Chemistry:
3-formyl-1H-Indole-4-carboxylic acid methyl ester is employed as a component in medicinal chemistry for the design and synthesis of bioactive molecules. Its properties enable it to be integrated into the structures of potential therapeutic agents, aiding in the discovery of new treatments for various diseases.
It is crucial to handle 3-formyl-1H-Indole-4-carboxylic acid methyl ester with care due to its potential hazardous properties, ensuring that all safety precautions are strictly followed during its use in research and industrial applications.

InChI:InChI=1/C11H9NO3/c1-15-11(14)8-3-2-4-9-10(8)7(6-13)5-12-9/h2-6,12H,1H3

Upstream product

• 67-56-1 methanol 
• 141692-10-6 (3-formylindol-4-yl)thallium (III) bistrifluoroacetate 
• 39830-66-5 methyl 1H-indole-4-carboxylate 
• 68-12-2 N,N-dimethyl-formamide 
• 107-06-2 1,2-dichloro-ethane 
• 93-61-8 N-methyl-N-phenylformamide 
• 100-61-8 N-methylaniline 
• 59382-59-1 2-methyl-3-nitro-benzoic acid methyl ester 
• 12591-02-5 phosphoryl oxychloride on N,N-dimethylformamide 

Downstream Products

• 110811-32-0 4-methoxycarbonyl-indole-3-carboxylic acid 
• 65923-20-8 3-formyl-1-methyl-1H-indole-4-carboxylic acid methyl ester 
• 1195784-92-9 C₂₀H₁₆N₄O₂ 
• 1428129-86-5 methyl 1-(5-chloro-2-((4-chloro-2-fluorobenzyl)oxy)benzyl)-3-(hydroxymethyl)-1H-indole-4-carboxylate 
• 1428127-77-8 sodium 1-(5-chloro-2-((4-chloro-2-fluorobenzyl)oxy)benzyl)-3-(hydroxymethyl)-1H-indole-4-carboxylate 
• 1428129-90-1 methyl 1-(5-chloro-2-((4-chloro-2-fluorobenzyl)oxy)benzyl)-3-(2-methoxyvinyl)-1H-indole-4-carboxylate 
• 1428129-92-3 methyl 1-(5-chloro-2-((4-chloro-2-fluorobenzyl)oxy)benzyl)-3-(2-oxoethyl)-1H-indole-4-carboxylate 
• 1428129-94-5 1-(5-chloro-2-((4-chloro-2-fluorobenzyl)oxy)benzyl)-3,4-dihydrooxepino[5,4,3-cd]indol-6(1H)-one 
• 1428127-90-5 sodium 1-(5-chloro-2-((4-chloro-2-fluorobenzyl)oxy)benzyl)-3-(2-hydroxyethyl)-1H-indole-4-carboxylate 
• 1428130-08-8 (E)-methyl 1-(5-chloro-2-((4-chloro-2-fluorobenzyl)oxy)benzyl)-3-(3-ethoxy-3-oxoprop-1-en-1-yl)-1H-indole-4-carboxylate 
• 1428129-84-3 methyl 1-(5-chloro-2-((4-chloro-2-fluorobenzyl)oxy)benzyl)-3-formyl-1H-indole-4-carboxylate 
• 53269-34-4 1,3,4,5-tetrahydro-pyrrolo[4,3,2-de]isoquinoline 
• 53462-75-2 3,4-dihydro-1H-pyrrolo[4,3,2-de]isoquinolin-5-one 
• 1059128-98-1 4-ethyl-1-(phenylsulfonyl)-1,3,4,5-tetrahydropyrrolo[4,3,2-de]isoquinoline trifluoroacetate 

Relevant academic research and scientific papers

5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE

Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabet

A class of compounds with inhibitory activity PARP, process for their preparation and use

The invention relates to the field of pharmacochemistry and pharmacotherapeutics and particularly relates to a tricyclic indole compound (I) with PARP (Poly-ADP-Ribose Polymerase) inhibiting activity, a preparation method and an application thereof. The R

5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE

Provided are 5-HT2C receptor agonists. Also provided are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided are compositions comprising a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent, and methods for reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reducing weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use comprising administering a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent.

EP1 RECEPTOR LIGANDS

The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

Discovery of a highly selective FLT3 kinase inhibitor from phenotypic cell viability profiling

We discovered a novel molecular framework 4 containing a heterobiaryl pyrazolopyridine moiety as a selective FLT3 kinase inhibitor from phenotype-based viability profiling. Compound 4g showed outstanding selectivity in cellular cytotoxicity against MV-4-11 leukemic cells via the induction of apoptosis. The hypothesis-driven deconvolution elucidated that compound 4g selectively blocked the phosphorylation of FLT3 and its downstream effectors, such as ERK and STAT5, only in MV-4-11 cells. The inhibitory effect of 4g on in vitro enzyme function and FLT3 phosphorylation in cells proved that FLT3 kinase is a direct molecular target of 4g. Finally, the kinase activity profiling of 4g verified its excellent selectivity toward FLT3 over 40 representative kinases, including the receptor tyrosine kinase (RTK) family. The Royal Society of Chemistry 2013.

Mild and selective Ru-catalyzed formylation and Fe-catalyzed acylation of free (N-H) indoles using anilines as the carbonyl source

C3-selective formylation and acylation of free (N-H) indoles under mild conditions can be achieved by using Ru- and Fe-catalyzed oxidative coupling of free (N-H) indoles with anilines, respectively. Both processes are operationally simple, compatible with a variety of functional groups and generally provide the desired products in good yields. 13C-labeling experiments unambiguously established that the carbonylic carbon in the formylation products originated from methyl group of N-methyl aniline.

An efficient one-step synthesis of heterobiaryl pyrazolo[3,4-u] pyridines via indole ring opening

A mild one-step synthetic method to access privileged heterobiaryl pyrazolo[3,4-b]pyridines from indole-3-carboxaldehyde derivatives and a variety of aminopyrazoles has been developed. This novel method constructs heterobiaryls with the wide scope of substrate generality and excellent regioselectivity via indole ring opening.

TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY

The present invention relates to novel compounds of formula (I): wherein R1, R2, R3, R4, and R5 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their

1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors

KDR kinase inhibition is considered to play an important role in regulating angiogenesis, which is vital for the survival and proliferation of tumor cells. Recently we disclosed a structure-based kinase inhibitor design strategy which led to the identification of a new class of VEGFR-2/KDR kinase inhibitors bearing heterocyclic substituted pyrazolones as the core template. Instability in a rat S9 preparation and poor iv PK profiles for most of these inhibitors necessitated exploration of new pyrazolones to identify new analogs with improved metabolic stability. Optimization of the heterocyclic moiety led to the identification of the thiadiazole series of pyrazolones (D) as potent VEGFR-2/KDR kinase inhibitors. SAR modifications, kinase selectivity profiling, and structural elements for improved PK properties were explored. Oral bioavailability up to 29% was achieved in the rat. Modeling results based on the Glide XP docking approach supported our postulation regarding the interaction of the lactam segment of the pyrazolones with the hinge region of the KDR kinase.

Tricyclic inhibitors of poly(ADP-ribose) polymerases

Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapuetics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and nuerodegenerative disease. STR1As cancer therapuetics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.